Apr 19, 2021 | Anti-METH antibody, IXT-m200, General News
IXT-m200 produced significant changes in primary endpoint of methamphetamine pharmacokinetics, with favorable data for secondary endpoints and safety LITTLE ROCK, AR, USA, April 19, 2021 – InterveXion Therapeutics, a private clinical-stage biopharmaceutical...
Oct 5, 2020 | Anti-METH antibody, IXT-m200, General News, Grants
“Meth-OD” trial will be first known clinical trial specifically for patients suffering from methamphetamine overdose LITTLE ROCK, ARKANSAS, USA, October 5, 2020 /EINPresswire.com/ — InterveXion Therapeutics, a clinical-stage biopharmaceutical...
May 5, 2020 | Anti-METH antibody, IXT-m200, Grants
Grant fully funds manufacture of clinical supplies for Phase 2b clinical study and supports initiation of development of new subcutaneous formulation of IXT-m200 Little Rock, AR (01 May 2020) – InterveXion Therapeutics, a private clinical-stage biopharmaceutical...
Feb 6, 2020 | Anti-METH antibody, IXT-m200
Source: Part 2: Immunotherapies—A New Tool To Treat Methamphetamine Addiction? | National Institute on Drug Abuse...
Feb 6, 2020 | Anti-METH antibody, IXT-m200
Source: Part 1: Immunotherapies—A New Tool To Treat Methamphetamine Addiction? | National Institute on Drug Abuse...
Feb 5, 2020 | Anti-METH antibody, IXT-m200, METH in the news
She [Nora Volkow] lays out the range of research for drugs to treat both the acute, overdose episodes and chronic treatment. To prevent an overdose, she says the U.S. government is funding trials of a drug that could be injected into someone dangerously high on meth....
Recent Comments